MARKET

PBYI

PBYI

Puma Biotechnology Inc
NASDAQ
8.11
+0.44
+5.74%
After Hours: 8.11 0 0.00% 16:43 06/26 EDT
OPEN
7.67
PREV CLOSE
7.67
HIGH
8.23
LOW
7.67
VOLUME
1.10M
TURNOVER
--
52 WEEK HIGH
8.41
52 WEEK LOW
3.030
MARKET CAP
412.79M
P/E (TTM)
17.00
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PBYI last week (0615-0619)?
Weekly Report · 5d ago
Puma Biotechnology Shareholders Back Governance, Reject Warrant Extension
TipRanks · 06/16 20:40
Puma Biotechnology shareholders reject extension of CEO Auerbach warrant term
PUBT · 06/16 20:08
Puma Bio director Dorval Allison disposes of 11,610 shares for $83,586.02
PUBT · 06/16 00:09
Weekly Report: what happened at PBYI last week (0608-0612)?
Weekly Report · 06/15 09:04
Weekly Report: what happened at PBYI last week (0601-0605)?
Weekly Report · 06/08 09:04
Puma Biotechnology grants inducement RSUs covering 7,000 shares to new hires
PUBT · 06/03 21:00
PUMA BIOTECHNOLOGY REPORTS INDUCEMENT AWARDS UNDER NASDAQ LISTING RULE 5635(C)(4)
Reuters · 06/03 21:00
More
About PBYI
Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of products to enhance cancer care. The Company is commercializing NERLYNX, an oral version of neratinib, for the treatment of certain HER2-positive breast cancers. NERLYNX is approved in the United States for two indications: the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy and for use in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. The Company is focused on the global development and commercialization of alisertib. Alisertib is a selective, small-molecule inhibitor of Aurora Kinase A that is designed to disrupt mitosis, leading to apoptosis of rapidly proliferating tumor cells.

Webull offers Puma Biotechnology Inc stock information, including NASDAQ: PBYI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PBYI stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PBYI stock methods without spending real money on the virtual paper trading platform.